Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

Asthma Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00048022
• Other study ID #: BA16630
• Status: Completed
• Phase: Phase 2
• First received: October 24, 2002
• Last updated: June 15, 2017
• Start date: October 25, 2002
• Est. completion date: February 2, 2004

Study information

• Verified date: February 2017
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the anti-inflammatory action and safety of Ro 27-2441 (study drug) in asthmatic patients currently taking inhaled corticosteroids. The research is being conducted at up to 40 clinical research sites in the US. Study participants will have a number of visits to a research site over a 4-month period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: February 2, 2004
• Est. primary completion date: February 2, 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Persistent asthma for more than 1 year

• Currently receiving treatment with a stable dose of inhaled corticosteroids for more than 3 months

• In good health as demonstrated by medical history and physical exam

• Negative urine pregnancy test

• Commitment to use two forms of effective contraception simultaneously throughout the study duration and for 1 month after discontinuing therapy

Exclusion Criteria:

• Hospitalization for treatment of asthma and/or treatment with oral/injectable corticosteroids within 3 months before the start of the study

• Undergoing allergy shots unless on a stable maintenance dose for 3 months before the start of the study

• History of chronic pulmonary diseases other than asthma

• Treatment of conditions other than asthma with oral corticosteroids within 1 month of the start of the study

• Current tobacco usage

• Smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked)

• History or evidence of drug or alcohol abuse

• Diagnosis or evidence of an infectious illness within one month of Visit 1

• Clinically significant diseases as assessed by the study doctor

• Participation in another clinical study with an experimental drug within one month of start of the study

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Dual Integrin Antagonist

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Puerto Rico,